Wang Yaomin, Scarneo Scott A, Kim Shin Hyung, Zhang Xin, Chen Jiegen, Yang Kelly W, Hughes Philip, Haystead Timothy, Nackley Andrea G
Department of Anesthesiology, Center for Translational Pain Medicine, Duke University School of Medicine, Durham, NC, United States.
Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC, United States.
Pain. 2022 Jun 1;163(6):1091-1101. doi: 10.1097/j.pain.0000000000002511. Epub 2021 Oct 12.
Heat shock protein 90 (Hsp90) is a ubiquitously expressed integral cellular protein essential for regulating proteomic stress. Previous research has shown that Hsp90 regulates critical signaling pathways underlying chronic pain and inflammation. Recent discovery of membrane bound ectopic Hsp90 (eHsp90) on tumor cells has shown that Hsp90 induction to the plasma membrane can stabilize disease-relevant proteins. Here, we characterize eHsp90 expression in a mouse model of inflammation and demonstrate its role in nociception and pain. We found that intraplantar complete Freund adjuvant (CFA) induced robust expression of eHsp90 on the cell membranes of primary afferent nociceptors located in the L3-L5 dorsal root ganglia (DRG), bilaterally, with minimal to no expression in other tissues. Complete Freund adjuvant-induced increases in eHsp90 expression on lumbar DRG were significantly greater in females compared with males. Furthermore, exogenous Hsp90 applied to primary Pirt-GCaMP3 nociceptors induced increases in calcium responses. Responses were estrogen-dependent such that greater activity was observed in female or estrogen-primed male nociceptors compared with unprimed male nociceptors. Treatment of mice with the selective eHsp90 inhibitor HS-131 (10 nmol) significantly reversed CFA-induced mechanical pain, thermal heat pain, and hind paw edema. Notably, a higher dose (20 nmol) of HS-131 was required to achieve analgesic and anti-inflammatory effects in females. Here, we provide the first demonstration that inflammation leads to an upregulation of eHsp90 on DRG nociceptors in a sex-dependent manner and that inhibition of eHsp90 reduces nociceptor activity, pain, and inflammation. Thus, eHsp90 represents a novel therapeutic axis for the development of gender-tailored treatments for inflammatory pain.
热休克蛋白90(Hsp90)是一种在细胞中普遍表达的整合蛋白,对调节蛋白质组应激至关重要。先前的研究表明,Hsp90调节慢性疼痛和炎症背后的关键信号通路。最近在肿瘤细胞上发现膜结合异位Hsp90(eHsp90)表明,Hsp90向质膜的诱导可稳定与疾病相关的蛋白质。在这里,我们表征了炎症小鼠模型中eHsp90的表达,并证明了其在伤害感受和疼痛中的作用。我们发现,足底注射完全弗氏佐剂(CFA)可在双侧L3-L5背根神经节(DRG)中位于初级传入伤害感受器细胞膜上诱导eHsp90的强烈表达,而在其他组织中表达极少或无表达。与雄性相比,完全弗氏佐剂诱导的腰椎DRG上eHsp90表达的增加在雌性中显著更大。此外,将外源性Hsp90应用于初级Pirt-GCaMP3伤害感受器可诱导钙反应增加。反应是雌激素依赖性的,因此与未用雌激素预处理的雄性伤害感受器相比,在雌性或雌激素预处理的雄性伤害感受器中观察到更大的活性。用选择性eHsp90抑制剂HS-131(10 nmol)治疗小鼠可显著逆转CFA诱导的机械性疼痛、热痛和后爪水肿。值得注意的是,需要更高剂量(20 nmol)的HS-131才能在雌性中实现镇痛和抗炎作用。在这里,我们首次证明炎症以性别依赖性方式导致DRG伤害感受器上eHsp90上调,并且抑制eHsp90可降低伤害感受器活性、疼痛和炎症。因此,eHsp90代表了开发针对炎症性疼痛的性别定制治疗方法的新治疗轴。